“…Regardless of aforementioned limitations, the included studies investigated several inflammatory mediators, such as pro-inflammatory mediators (interleukin-1 beta (IL-1b), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-a), cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2) and transforming growth factor beta (TGF-b)) (10)(11)19,21,(23)(24)27,33,35,39,(47)(48)(50)(51)(52)(53), as well as anti-inflammatory mediator [interleukin-10 (IL-10)] (21,30,48), involved in tendon repair or tendinitis condition. Other inflammatory mediator factors were also studied such as vascular endothelium growth factor (VEGF), metalloproteinase-1 matrix (MMP1), metalloproteinase-2 matrix (MMP-2), metalloproteinase-3 matrix (MMP-3), metalloproteinase-9 matrix (MMP-9), metalloproteinase-13 matrix (MMP13) and induced nitric oxide synthase (i-NOS) (10)(11)(28)(29)(34)(35)37,39,54) that contribute to the understanding of how PBMT can benefited tendon repair or tendinitis condition. In this context, depending on wavelength, dose (Joule), treatment frequency and tendon repair phase, PBMT, either by LLLT or by LED, can modulate levels of gene expression (mRNA), enzymatic activity of metalloproteinases (MMPs) (11,(27)(28)35,39) and collagen synthesis (30,37).…”